Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect

FASEB Journal

Volumn 23, Issue 9, 2009, Pages 2844-2854

  Cao, Peirang ^a   Hanai, Jun Ichi ^a   Tanksale, Preeti ^a   Imamura, Shintaro ^b   Vikas P Sukhatme, ^a   Lecker, Stewart H ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b FISHERIES RESEARCH AGENCY   (Japan)

Author keywords

Atrophy; Farnesylation

Indexed keywords

ATROGIN 1; CHOLESTEROL; FARNESOL; GERANYLGERANIOL; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN;

ANIMAL CELL CULTURE; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; EMBRYO; FISH; MOUSE; MUSCLE CELL; MUSCLE INJURY; MYOBLAST; MYOPATHY; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN MODIFICATION; SIGNAL TRANSDUCTION; ZEBRA FISH;

ANIMALS; CELLS, CULTURED; F-BOX PROTEINS; GTP-BINDING PROTEINS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MICE; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MUSCULAR ATROPHY; PRENYLATION; SKP CULLIN F-BOX PROTEIN LIGASES; TRANSCRIPTIONAL ACTIVATION; ZEBRAFISH; ZEBRAFISH PROTEINS;

ANIMALIA; DANIO RERIO;

EID: 70349323604     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.08-128843     Document Type: Article

References (64)

1. Staffa, J. A., Chang, J., and Green, L. (2002) Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med. 346, 539-540
2. Thompson, P. D., Clarkson, P., and Karas, R. H. (2003) Statin-associated myopathy. JAMA 289, 1681-1690
3. Ballantyne, C. M., Corsini, A., Davidson, M. H., Holdaas, H., Jacobson, T. A., Leitersdorf, E., Marz, W., Reckless, J. P., and Stein, E. A. (2003) Risk for myopathy with statin therapy in high-risk patients. Arch. Intern. Med. 163, 553-564 (Pubitemid 36314342)
4. Graham, D. J., Staffa, J. A., Shatin, D., Andrade, S. E., Schech, S. D., La Grenade, L., Gurwitz, J. H., Chan, K. A., Goodman, M. J., and Platt, R. (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292, 2585-2590 (Pubitemid 39577514)
5. Phillips, P. S., Haas, R. H., Bannykh, S., Hathaway, S., Gray, N. L., Kimura, B. J., Vladutiu, G. D., and England, J. D. (2002) Statin-associated myopathy with normal creatine kinase levels. Ann. Intern. Med. 137, 581-585
6. Antons, K. A., Williams, C. D., Baker, S. K., and Phillips, P. S. (2006) Clinical perspectives of statin-induced rhabdomyolysis. Am. J. Med. 119, 400-409
7. Foley, K. A., Massing, M. W., Simpson, R. J., Jr., Alexander, C. M., and Markson, L. E. (2004) Population implications of changes in lipid management in patients with coronary heart disease. Am. J. Cardiol. 93, 193-195 (Pubitemid 38058727)
8. O'Meara, J. G., Kardia, S. L., Armon, J. J., Brown, C. A., Boerwinkle, E., and Turner, S. T. (2004) Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch. Intern. Med. 164, 1313-1318 (Pubitemid 38828882)
9. Buettner, C., Davis, R. B., Leveille, S. G., Mittleman, M. A., and Mukamal, K. J. (2008) Prevalence of musculoskeletal pain and statin use. J. Gen. Intern. Med. 23, 1182-1186
10. Baker, S. K., and Tarnopolsky, M. A. (2001) Statin myopathies: pathophysiologic and clinical perspectives. Clin. Invest. Med. 24, 258-272
11. Baker, S. K. (2005) Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve 31, 572-580
12. Buettner, C., and Lecker, S. H. (2008) Molecular basis for statin-induced muscle toxicity: implications and possibilities. Pharmacogenomics 9, 1133-1142
13. Mitch, W. E., and Goldberg, A. L. (1996) Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. New Engl. J. Med. 335, 1897-1905
14. Attaix, D., Mosoni, L., Dardevet, D., Combaret, L., Mirand, P. P., and Grizard, J. (2005) Altered responses in skeletal muscle protein turnover during aging in anabolic and catabolic periods. Int. J. Biochem. Cell Biol. 37, 1962-1973 (Pubitemid 41206814)
15. Hanai, J. I., Cao, P., Tanksale, P., Imamura, S., Koshimizu, E., Zhao, J., Kishi, S., Yamashita, M., Phillips, P. S., Sukhatme, V. P., and Lecker, S. H. (2007) The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J. Clin. Invest. 117, 3940-3951 (Pubitemid 350224103)
16. Lecker, S. H., Solomon, V., Mitch, W. E., and Goldberg, A. L. (1999) Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J. Nutr. 129, 227S-237S (Pubitemid 29035981)
17. Gomes, M. D., Lecker, S. H., Jagoe, R. T., Navon, A., and Goldberg, A. L. (2001) Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl. Acad. Sci. U. S. A. 98, 14440-14445 (Pubitemid 33121410)
18. Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K., Nunez, L., Clarke, B. A., Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., Pan, Z. Q., Valenzuela, D. M., DeChiara, T. M., Stitt, T. N., Yancopoulos, G. D., and Glass, D. J. (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294, 1704-1708 (Pubitemid 33104839)
19. Tintignac, L. A., Lagirand, J., Batonnet, S., Sirri, V., Leibovitch, M. P., and Leibovitch, S. A. (2005) Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. J. Biol. Chem. 280, 2847-2856 (Pubitemid 40189393)
20. Li, H. H., Kedar, V., Zhang, C., McDonough, H., Arya, R., Wang, D. Z., and Patterson, C. (2004) Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J. Clin. Invest. 114, 1058-1071 (Pubitemid 39578695)
21. Lagirand-Cantaloube, J., Offner, N., Csibi, A., Leibovitch, M. P., Batonnet-Pichon, S., Tintignac, L. A., Segura, C. T., and Leibovitch, S. A. (2008) The initiation factor eIF3-f is a major target for Atrogin1/MAFbx function in skeletal muscle atrophy. EMBO J. 27, 1266-1276 (Pubitemid 351574748)
22. Li, H. H., Willis, M. S., Lockyer, P., Miller, N., McDonough, H., Glass, D. J., and Patterson, C. (2007) Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins. J. Clin. Invest. 117, 3211-3223 (Pubitemid 350096979)
23. Urso, M. L., Clarkson, P. M., Hittel, D., Hoffman, E. P., and Thompson, P. D. (2005) Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler. Thromb. Vasc. Biol. 25, 2560-2566 (Pubitemid 43732279)
24. Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H., and Goldberg, A. L. (2004) Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117, 399-412 (Pubitemid 38534545)
25. Siddals, K. W., Marshman, E., Westwood, M., and Gibson, J. M. (2004) Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein prenylation and receptor glycosylation pathways. J. Biol. Chem. 279, 38353-38359 (Pubitemid 39295984)
26. Liao, J. K. (2002) Isoprenoids as mediators of the biological effects of statins. J. Clin. Invest. 110, 285-288
27. Kaufmann, P., Torok, M., Zahno, A., Waldhauser, K. M., Brecht, K., and Krahenbuhl, S. (2006) Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol. Life Sci. 63, 2415-2425 (Pubitemid 44653050)
28. Nambudiri, A. M., Ranganathan, S., and Rudney, H. (1980) The role of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in the regulation of ubiquinone synthesis in human fibroblasts. J. Biol. Chem. 255, 5894-5899 (Pubitemid 10023601)
29. Berthold, H. K., Naini, A., Di Mauro, S., Hallikainen, M., Gylling, H., Krone, W., and Gouni-Berthold, I. (2006) Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf. 29, 703-712 (Pubitemid 44175041)
30. Lamperti, C., Naini, A. B., Lucchini, V., Prelle, A., Bresolin, N., Moggio, M., Sciacco, M., Kaufmann, P., and DiMauro, S. (2005) Muscle coenzyme Q10 level in statin-related myopathy. Arch. Neurol. 62, 1709-1712 (Pubitemid 41626667)
31. Bdolah, Y., Segal, A., Tanksale, P., Karumanchi, S. A., and Lecker, S. H. (2007) Atrophy-related ubiquitin ligases atrogin-1 and MuRF-1 are associated with uterine smooth muscle involution in the postpartum period. Am. J. Physiol. 292, R971-976 (Pubitemid 46207754)
32. Okuno, Y., Huettner, C. S., Radomska, H. S., Petkova, V., Iwasaki, H., Akashi, K., and Tenen, D. G. (2002) Distal elements are critical for human CD34 expression in vivo. Blood 100, 4420-4426 (Pubitemid 35429680)
33. Yang, H., Menconi, M. J., Wei, W., Petkova, V., and Hasselgren, P. O. (2005) Dexamethasone upregulates the expression of the nuclear cofactor p300 and its interaction with C/EBPbeta in cultured myotubes. J. Cell. Biochem. 94, 1058-1067 (Pubitemid 41420264)
34. Hanai, J., Gloy, J., Karumanchi, S. A., Kale, S., Tang, J., Hu, G., Chan, B., Ramchandran, R., Jha, V., Sukhatme, V. P., and Sokol, S. (2002) Endostatin is a potential inhibitor of Wnt signaling. J. Cell Biol. 158, 529-539 (Pubitemid 34851711)
35. Westerfield, M. (1993) The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish Danio (Brachydanio) rerio, Institute of Neuroscience, University of Oregon, Eugene, OR, USA
36. Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B., and Schilling, T. F. (1995) Stages of embryonic development of the zebrafish. Dev. Dyn. 203, 253-310
37. Crow, M. T., and Stockdale, F. E. (1986) The developmental program of fast myosin heavy chain expression in avian skeletal muscles. Dev. Biol. 118, 333-342
38. Devoto, S. H., Melancon, E., Eisen, J. S., and Westerfield, M. (1996) Identification of separate slow and fast muscle precursor cells in vivo, prior to somite formation. Development 122, 3371-3380 (Pubitemid 26395980)
39. Birely, J., Schneider, V. A., Santana, E., Dosch, R., Wagner, D. S., Mullins, M. C., and Granato, M. (2005) Genetic screens for genes controlling motor nerve-muscle development and interactions. Dev. Biol. 280, 162-176 (Pubitemid 40342750)
40. Pan, H. Y., DeVault, A. R., Wang-Iverson, D., Ivashkiv, E., Swanson, B. N., and Sugerman, A. A. (1990) Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J. Clin. Pharmacol. 30, 1128-1135
41. Holstein, S. A., Knapp, H. R., Clamon, G. H., Murry, D. J., and Hohl, R. J. (2006) Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother. Pharmacol. 57, 155-164
42. Flint, O. P., Masters, B. A., Gregg, R. E., and Durham, S. K. (1997) Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol. Appl. Pharmacol. 145, 91-98
43. Matzno, S., Yamauchi, T., Gohda, M., Ishida, N., Katsuura, K., Hanasaki, Y., Tokunaga, T., Itoh, H., and Nakamura, N. (1997) Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts. J. Lipid Res. 38, 1639-1648 (Pubitemid 27427661)
44. Crick, D. C., Andres, D. A., and Waechter, C. J. (1997) Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation. Biochem. Biophys. Res. Commun. 237, 483-487
45. Ren, Z., Elson, C. E., and Gould, M. N. (1997) Inhibition of type I and type II geranylgeranyl-protein transferases by the monoterpene perillyl alcohol in NIH3T3 cells. Biochem. Pharmacol. 54, 113-120 (Pubitemid 27353228)
46. Sakamoto, K., Honda, T., Yokoya, S., Waguri, S., and Kimura, J. (2007) Rab-small GTPases are involved in fluvastatin and pravastatin- induced vacuolation in rat skeletal myofibers. FASEB J. 21, 4087-4094 (Pubitemid 350232365)
47. Baba, T. T., Nemoto, T. K., Miyazaki, T., and Oida, S. (2008) Simvastatin suppresses the differentiation of C2C12 myoblast cells via a Rac pathway. J. Muscle Res. Cell Motil. 29, 127-134
48. Takai, Y., Sasaki, T., and Matozaki, T. (2001) Small GTP-binding proteins. Physiol. Rev. 81, 153-208
49. Ivorra, C., Kubicek, M., Gonzalez, J. M., Sanz-Gonzalez, S. M., Alvarez-Barrientos, A., O'Connor, J. E., Burke, B., and Andres, V. (2006) A mechanism of AP-1 suppression through interaction of c-Fos with lamin A/C. Genes Dev. 20, 307-320 (Pubitemid 43200285)
50. Wang, L., Liu, F., and Adamo, M. L. (2001) Cyclic AMP inhibits extracellular signal-regulated kinase and phosphatidylinositol 3-kinase/Akt pathways by inhibiting Rap1. J. Biol. Chem. 276, 37242-37249 (Pubitemid 37384142)
51. Buerger, C., DeVries, B., and Stambolic, V. (2006) Localization of Rheb to the endomembrane is critical for its signaling function. Biochem. Biophys. Res. Commun. 344, 869-880
52. Hattori, M., and Minato, N. (2003) Rap1 GTPase: functions, regulation, and malignancy. J. Biochem. 134, 479-484 (Pubitemid 37442869)
53. Fernandez, M., Sanchez-Franco, F., Palacios, N., Sanchez, I., and Cacicedo, L. (2005) IGF-I and vasoactive intestinal peptide (VIP) regulate cAMP-response element-binding protein (CREB)-dependent transcription via the mitogen-activated protein kinase (MAPK) pathway in pituitary cells: requirement of Rap1. J. Mol. Endocrinol. 34, 699-712 (Pubitemid 40903595)
54. Romano, D., Pertuit, M., Rasolonjanahary, R., Barnier, J. V., Magalon, K., Enjalbert, A., and Gerard, C. (2006) Regulation of the RAP1/RAF-1/ extracellularly regulated kinase-1/2 cascade and prolactin release by the phosphoinositide 3-kinase/AKT pathway in pituitary cells. Endocrinology 147, 6036-6045 (Pubitemid 44833523)
55. Van Kolen, K., Gilany, K., Moens, L., Esmans, E. L., and Slegers, H. (2006) P2Y12 receptor signalling towards PKB proceeds through IGF-I receptor cross-talk and requires activation of Src, Pyk2 and Rap1. Cell. Signal. 18, 1169-1181 (Pubitemid 43674032)
56. Pizon, V., and Baldacci, G. (2000) Rap1A protein interferes with various MAP kinase activating pathways in skeletal myogenic cells. Oncogene 19, 6074-6081 (Pubitemid 32039382)
57. Ulucan, C., Wang, X., Baljinnyam, E., Bai, Y., Okumura, S., Sato, M., Minamisawa, S., Hirotani, S., and Ishikawa, Y. (2007) Developmental changes in gene expression of Epac and its upregulation in myocardial hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 293, H1662-1672 (Pubitemid 47367213)
58. Castro, A. F., Rebhun, J. F., Clark, G. J., and Quilliam, L. A. (2003) Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J. Biol. Chem. 278, 32493-32496
59. Maurer-Stroh, S., Koranda, M., Benetka, W., Schneider, G., Sirota, F. L., and Eisenhaber, F. (2007) Towards complete sets of farnesylated and geranylgeranylated proteins. PLoS Comput. Biol. 3, e66 (Pubitemid 46683447)
60. Li, Y., Inoki, K., and Guan, K. L. (2004) Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity. Mol. Cell. Biol. 24, 7965-7975 (Pubitemid 39167447)
61. Mieulet, V., Roceri, M., Espeillac, C., Sotiropoulos, A., Ohanna, M., Oorschot, V., Klumperman, J., Sandri, M., and Pende, M. (2007) S6 kinase inactivation impairs growth and translational target phosphorylation in muscle cells maintaining proper regulation of protein turnover. Am. J. Physiol. Cell Physiol. 293, C712-722 (Pubitemid 47235195)
62. Tomasetti, M., Alleva, R., Solenghi, M. D., and Littarru, G. P. (1999) Distribution of antioxidants among blood components and lipoproteins: significance of lipids/CoQ10 ratio as a possible marker of increased risk for atherosclerosis. Biofactors 9, 231-240 (Pubitemid 29289001)
63. Marcoff, L., and Thompson, P. D. (2007) The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J. Am. Coll. Cardiol. 49, 2231-2237 (Pubitemid 46856819)
64. Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F., Gut, I., Lathrop, M., and Collins, R. (2008) SLCO1B1 variants and statin-induced myopathy - a genomewide study. N. Engl. J. Med. 359, 789-799